Dashboard
Weak Long Term Fundamental Strength with a -204.42% CAGR growth in Operating Profits over the last 5 years
- The company has been able to generate a Return on Equity (avg) of 5.75% signifying low profitability per unit of shareholders funds
Stock is technically in a Bearish range
Risky - Negative Operating Profits
Consistent Underperformance against the benchmark over the last 3 years
Stock DNA
Pharmaceuticals & Biotechnology
INR 131 Cr (Micro Cap)
NA (Loss Making)
40
0.00%
0.51
-5.65%
0.63
Total Returns (Price + Dividend) 
Latest dividend: 1 per share ex-dividend date: Jul-20-2023
Risk Adjusted Returns v/s 
Returns Beta
News

Natural Capsules Ltd Forms Death Cross, Signalling Potential Bearish Trend
Natural Capsules Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross—a technical pattern where the 50-day moving average crosses below the 200-day moving average—indicating a potential shift towards a prolonged bearish trend. This development comes amid deteriorating fundamentals and weak price performance, raising concerns about the stock’s near- and long-term outlook.
Read More
Natural Capsules Ltd Locks at Lower Circuit With 5.0% Loss — Sellers Queue, No Buyers in Sight
At Rs 126.19, sellers were still queuing — but there were no buyers willing to take the other side. Natural Capsules Ltd locked at its lower circuit of 5.0% on 20 Nov 2026, with unfilled sell orders and a frozen price that capped losses for the day.
Read More
Natural Capsules Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals
Natural Capsules Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Sell to Strong Sell as of 19 Nov 2026. This shift reflects a complex interplay of improved quarterly financials contrasted by persistent long-term fundamental weaknesses and mixed technical indicators, signalling caution for investors amid ongoing volatility.
Read More Announcements 
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
19-Nov-2026 | Source : BSEPursuant to Regulation 30 and Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements)
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011
16-Nov-2026 | Source : BSEThe Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Sunil Laxminarayana Mundra
Announcement under Regulation 30 (LODR)-Investor Presentation
15-Nov-2026 | Source : BSEPlease find enclosed herewith copy of Investor Presentation in connection with Q2 Financial Results.
Corporate Actions 
No Upcoming Board Meetings
Natural Capsules Ltd has declared 10% dividend, ex-date: 20 Jul 23
No Splits history available
No Bonus history available
Natural Capsules Ltd has announced 1:2 rights issue, ex-date: 11 Nov 21
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Sep 2026
Shareholding Compare (%holding) 
Promoters
None
Held by 0 Schemes
Held by 1 FIIs (0.08%)
Tajos Investments Private Limited (12.04%)
Sangeetha S (3.14%)
33.38%
Quarterly Results Snapshot (Consolidated) - Sep'26 - QoQ
QoQ Growth in quarter ended Sep 2026 is 5.01% vs -16.66% in Jun 2026
QoQ Growth in quarter ended Sep 2026 is 54.98% vs 21.45% in Jun 2026
Half Yearly Results Snapshot (Consolidated) - Sep'25
Growth in half year ended Sep 2025 is 13.18% vs 6.91% in Sep 2024
Growth in half year ended Sep 2025 is -1,25,600.00% vs -100.30% in Sep 2024
Nine Monthly Results Snapshot (Consolidated) - Dec'25
YoY Growth in nine months ended Dec 2025 is 3.64% vs 7.86% in Dec 2024
YoY Growth in nine months ended Dec 2025 is -17,600.00% vs -97.82% in Dec 2024
Annual Results Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is 10.63% vs 8.87% in Mar 2025
YoY Growth in year ended Mar 2026 is -3,246.51% vs -92.25% in Mar 2025